Jim Trenkle, Ph.D.
Jim joined Sanofi Ventures in 2020 with a background in R&D, commercialization, and early stage biotech investing and transactions. Prior to joining Sanofi, Jim was Vice President of Investments with Pivotal bioVenture Partners in San Francisco where he was board observer for several portfolio companies. Previous to Pivotal, Jim began his career with Gilead Sciences in 2007 where he held positions of increasing responsibility in medicinal chemistry, project and portfolio management, and commercial strategy, largely focused on hepatitis C and other liver diseases.
Jim currently serves on the Board of Directors for Inozyme and Yumanity Therapeutics.
Jim completed a BS in Honors Chemistry at University of Michigan, a PhD in Organic Chemistry at Massachusetts Institute of Technology, and holds an MBA from University of California Berkeley, Haas School of Business.